Clinical Trials Browser

Interventional × pegylated granulocyte colony-stimulating factor × Lymphoid × Clear all

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07224100 2026-02-20

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03907488 2025-12-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts

Hodgkin Disease

NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT06520163 2025-12-04

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Phase 3 Recruiting

Lymphoma, Non-Hodgkin

NCT03670966 2025-10-16

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1/2 Recruiting

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03220022 2025-07-18

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1 Active not recruiting

Lymphoma, AIDS-Related

NCT07020533 2025-06-13

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Phase 1 Not yet recruiting

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT05294055 2025-05-13

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05536154 2024-03-19

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Phase NA Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06026995 2023-09-07

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Phase 4 Unknown

Lymphoma

NCT05834751 2023-04-28

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Phase NA Unknown

Lymphoma

NCT04460508 2022-07-07

Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

Phase 2 Unknown

Lymphoma

NCT05156554 2021-12-14

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Phase NA Unknown

Lymphoma

NCT04497688 2020-08-04

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Phase NA Unknown

Lymphoma, Non-Hodgkin

NCT02953730 2016-11-03

The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents

Phase 4 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02905942 2016-09-19

PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Phase 4 Unknown

Lymphoma

NCT02805218 2016-06-20

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

Phase 4 Completed

Lymphoma